InVitae Corp (NVTA) - Medical Equipment - Deals and Alliances Profile

InVitae Corp (NVTA) - Medical Equipment - Deals and Alliances Profile


  • Products Id :- GDME443956D
  • |
  • Pages: 97
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Invitae Corp (Invitae), formerly Locus Development Inc, is a genetic information company which processes DNA-containing samples, analyzes information about patient-specific genetic variation and generates test reports for clinicians and their patients. The company's portfolio of diagnostic tests includes preimplantation and carrier screening for inherited disorders, miscarriage analysis, neurological disorders, metabolic disorders and pediatric and developmental disorders among others. Invitae specializes in offering exome analysis, panel and single gene genetic tests. It also provides proactive testing, genetic counseling resources, re-requistion testing, family variant testing and VUS resolution testing and clinical consult services. Invitae is headquartered in San Francisco, California, the US.

InVitae Corp (NVTA)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

InVitae Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 7

InVitae Corp, Medical Equipment Deals By Type, 2012 to YTD 2018 8

InVitae Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 9

InVitae Corp, Medical Equipment, Deals By Market, 2012 to YTD 2018 10

InVitae Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 11

InVitae Corp, Medical Equipment, Deal Details 13

Venture Financing 13

InVitae Raises USD16 Million in Venture Financing 13

InVitae Raises USD120 Million in Series F Venture Financing 14

Invitae Raises USD 40 Million In Series E Financing 16

Good Start Genetics Raises USD 14 Million In Initial Closing Of Series B Financing 18

Partnerships 19

CombiMatrix Enters Into Licensing Agreement With Cartagenia For Benchlab CNV Platform 19

Invitae and KEW Enter into Partnership 20

Invitae Enters into Clinical Research Agreement with TME Research 21

Good Start Genetics Enters into Marketing Agreement with Roche Diagnostics 22

CombiMatrix Enters into Distribution Agreement with Universal Diagnostic Labs 23

Good Start Genetics Enters into Agreement with IviGen and iGenomix 24

Good Start Genetics Enters Into Agreement With PerkinElmer To Provide GoodStart Select Carrier Screening Tests 25

Sequenom And CombiMatrix Enter Into Agreement To Market Chromosomal Microarray Analysis For Prenatal Testing 26

CombiMatrix Expands Co-Marketing Agreement With Pathology For Prenatal Tests 27

CombiMatrix Enters Into Co-Marketing Agreement With Pathology For Prenatal Tests 28

Good Start Genetics Enters into Licensing Agreement with Johns Hopkins University 29

Equity Offering 30

Invitae Prices Public Offering of Shares for USD50 Million 30

Invitae to Raise Funds through Public Offering of Shares 32

Invitae to Raise Funds through Public Offering of Shares 33

Invitae Raises USD73.5 Million in Private Placement of Shares and Preferred Shares 34

Invitae Raises USD50.6 Million in Public Offering of Shares 35

CombiMatrix Raises USD8 Million in Public Offering of Units 37

CombiMatrix Raises USD3.34 Million in Private Placement of Warrants 39

Invitae Raises USD117 Million in IPO 41

CombiMatrix Raise USD5 Million in Private Placement of Securities 43

CombiMatrix Completes Public Offering Of Units For USD 12 Million 45

CombiMatrix Completes Second Tranche Of Private Placement Of Preferred Shares For USD 1.2 Million 46

CombiMatrix Completes Private Placement Of Common Stock For USD 0.4 Million 47

CombiMatrix Completes Private Placement Of Units For USD 1.6 Million 48

CombiMatrix Completes Second Tranche Of Private Placement Of Series A Shares Of Preferred Stock 49

Acquisition 50

Invitae Acquires CombiMatrix for USD35 Million 50

Invitae to Acquire Good Start Genetics 52

Invitae Acquires AltaVoice 53

InVitae Corp-Key Competitors 54

InVitae Corp-Key Employees 55

InVitae Corp-Locations And Subsidiaries 56

Head Office 56

Other Locations & Subsidiaries 56

Recent Developments 57

Financial Announcements 57

Aug 07, 2018: Invitae reports more than 160% annual revenue growth driven by nearly 140% annual growth in volume in second quarter 2018 57

May 09, 2018: Invitae Reports 169% Revenue Growth Driven by 150% Growth in Volume in First Quarter 2018 58

Feb 12, 2018: Invitae reports over 150% volume and over 170% revenue growth for 2017 60

Jan 08, 2018: Invitae more than doubles annual volume, exceeds full-year 2017 guidance, and projects momentum to continue in 2018 62

Nov 06, 2017: Invitae Reports Double-Digit Sequential Volume and Revenue Growth in Third Quarter 2017 63

Aug 07, 2017: Invitae Reports Second Quarter 2017 Results 66

May 08, 2017: Invitae Exceeds 26,000 Samples Accessioned, Reports Revenue of USD 10.3 Million and Net Loss of USD 0.64 Per Share in First Quarter 2017 68

Mar 16, 2017: Oxford Finance Signs Loan and Security Agreement With Invitae 70

Feb 13, 2017: Invitae reports revenue of USD 9.2 million in fourth quarter 2016 and projects strong volume and revenue growth in 2017 71

Jan 06, 2017: Invitae meets annual volume guidance, projects doubling of volume in 2017, accelerates Genome Network by acquiring scalable patient-centered data company 73

Corporate Communications 74

Sep 11, 2018: Invitae names Chitra Nayak to its Board of Directors 74

May 25, 2017: Invitae Broadens Management Team to Scale Expanding Business and Meet Rising Demand 75

Mar 16, 2017: Oxford Finance Signs Loan and Security Agreement With Invitae 76

Jan 09, 2017: Invitae announces new leadership structure to drive global growth 77

Government and Public Interest 78

Jun 05, 2017: ASCO Data Shows Prostate Cancer Patients with Genetic Risk Factors Missed Under Current Testing Guidelines 78

Product News 79

Apr 10, 2018: Invitae research highlights utility of proactive genetic screening, importance of assessing secondary findings in genetic testing 79

Dec 05, 2017: Invitae to present findings at 2017 San Antonio Breast Cancer Symposium 82

Dec 05, 2017: Multigene Genetic Testing Improves Identification and Management of Hereditary Cancer Risk for Breast Cancer Patients and Their Families 83

Oct 30, 2017: Invitae Presents Validation of a Novel NGS-based Preimplantation Genetic Screening Technology to Identify the Most Frequent Chromosomal Causes of Miscarriage 84

Apr 28, 2017: New research suggests current genetic testing guidelines may miss breast cancer patients who could benefit from testing 86

Apr 20, 2017: Invitae announces expansion of its genetic test menu with addition of new tests and expanded panels for inherited metabolic and immune system disorders, including panels to confirm diagnoses suggested by newborn screening 88

Feb 17, 2017: New research suggests broader genetic testing of prostate cancer patients may be warranted to identify risk of an inherited mutation that might inform treatment 89

Other Significant Developments 91

Jun 13, 2018: Invitae Study of 143,000 Patients Shows Importance of Routinely Including Deletion and Duplication Detection with Sequencing in Genetic Testing 91

May 07, 2018: Genome Medical Enters Employer Market with Diverse Genetic Health Programs and Wave of New Partners 92

Feb 27, 2018: Invitae expands existing credit facility to provide up to USD 40.0 million in available growth capital 93

Oct 05, 2017: Invitae's new framework for classifying genetic variants aims to improve consistency of genetic test results industry-wide 94

Mar 30, 2017: Invitae announces introduction of exome testing 95

Mar 23, 2017: Invitae Expands Test Menu for Proactive Genetic Testing in Healthy Adults 96

Appendix 97

Methodology 97

About GlobalData 97

Contact Us 97

Disclaimer 97

List of Figures

InVitae Corp, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

InVitae Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

InVitae Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

InVitae Corp, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

InVitae Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 7

InVitae Corp, Medical Equipment, Deals by Type, 2012 to YTD 2018 8

InVitae Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 9

InVitae Corp, Medical Equipment, Deals by Market, 2012 to YTD 2018 10

List of Tables

InVitae Corp, Medical Equipment, Key Facts, 2017 2

InVitae Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

InVitae Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 7

InVitae Corp, Medical Equipment Deals By Type, 2012 to YTD 2018 8

InVitae Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 9

InVitae Corp, Deals By Market, 2012 to YTD 2018 10

InVitae Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 11

InVitae Raises USD16 Million in Venture Financing 13

InVitae Raises USD120 Million in Series F Venture Financing 14

Invitae Raises USD 40 Million In Series E Financing 16

Good Start Genetics Raises USD 14 Million In Initial Closing Of Series B Financing 18

CombiMatrix Enters Into Licensing Agreement With Cartagenia For Benchlab CNV Platform 19

Invitae and KEW Enter into Partnership 20

Invitae Enters into Clinical Research Agreement with TME Research 21

Good Start Genetics Enters into Marketing Agreement with Roche Diagnostics 22

CombiMatrix Enters into Distribution Agreement with Universal Diagnostic Labs 23

Good Start Genetics Enters into Agreement with IviGen and iGenomix 24

Good Start Genetics Enters Into Agreement With PerkinElmer To Provide GoodStart Select Carrier Screening Tests 25

Sequenom And CombiMatrix Enter Into Agreement To Market Chromosomal Microarray Analysis For Prenatal Testing 26

CombiMatrix Expands Co-Marketing Agreement With Pathology For Prenatal Tests 27

CombiMatrix Enters Into Co-Marketing Agreement With Pathology For Prenatal Tests 28

Good Start Genetics Enters into Licensing Agreement with Johns Hopkins University 29

Invitae Prices Public Offering of Shares for USD50 Million 30

Invitae to Raise Funds through Public Offering of Shares 32

Invitae to Raise Funds through Public Offering of Shares 33

Invitae Raises USD73.5 Million in Private Placement of Shares and Preferred Shares 34

Invitae Raises USD50.6 Million in Public Offering of Shares 35

CombiMatrix Raises USD8 Million in Public Offering of Units 37

CombiMatrix Raises USD3.34 Million in Private Placement of Warrants 39

Invitae Raises USD117 Million in IPO 41

CombiMatrix Raise USD5 Million in Private Placement of Securities 43

CombiMatrix Completes Public Offering Of Units For USD 12 Million 45

CombiMatrix Completes Second Tranche Of Private Placement Of Preferred Shares For USD 1.2 Million 46

CombiMatrix Completes Private Placement Of Common Stock For USD 0.4 Million 47

CombiMatrix Completes Private Placement Of Units For USD 1.6 Million 48

CombiMatrix Completes Second Tranche Of Private Placement Of Series A Shares Of Preferred Stock 49

Invitae Acquires CombiMatrix for USD35 Million 50

Invitae to Acquire Good Start Genetics 52

Invitae Acquires AltaVoice 53

InVitae Corp, Key Competitors 54

InVitae Corp, Key Employees 55

InVitae Corp, Subsidiaries 56

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

InVitae Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17743
Site License
USD 500 INR 35485
Corporate User License
USD 750 INR 53228

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com